• Explore /
  • Poster
  • / First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): Phase 1 results.

First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): Phase 1 results.

Abstract Poster

Authors

null

Melissa Lynne Johnson

Sarah Cannon Research Institute, Nashville, TN

Melissa Lynne Johnson , Tim Meyer , Daniel M. Halperin , Antonio Tito Fojo , Natalie Cook , Lawrence Scott Blaszkowsky , Benjamin L. Schlechter , James C. Yao , Yannis Jemiai , Kristina Kriksciukaite , Marsha Jones , Nneamaka Ezema , Laura Mei , Leila Alland , Matthew H. Kulke

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Neuroendocrine/Carcinoid

Clinical Trial Registration Number

NCT02936323

Citation

J Clin Oncol 36, 2018 (suppl; abstr 4097)

DOI

10.1200/JCO.2018.36.15_suppl.4097

Abstract #

4097

Poster Bd #

286

Abstract Disclosures

Similar Posters

First Author: Nataliya Volodymyrivna Uboha

First Author: Florence Atrafi

Poster

2017 ASCO Annual Meeting

Phase I study combining MLN8237 with nab-paclitaxel in patients with advanced solid malignancies.

Phase I study combining MLN8237 with nab-paclitaxel in patients with advanced solid malignancies.

First Author: Kian-Huat Lim

First Author: Jonathan R. Strosberg